Mutant of L1 protein of human papillomavirus type 39

US11427618B2 · kind B2 · utility

Assignees

• XIAMEN UNIVERSITY · CN
• Xiamen Innovax Biotech Co., Ltd. · CN

Inventors

• Shaowei Li · Potomac, US
• Daning Wang · Fujian, CN
• Zhiping Wang · Singapore, SG
• Xinlin Liu · Fujian, CN
• Jun Zhang · Xiamen, CN
• Ningshao Xia · Fujian, CN

Key dates

• Filing date: Jun 4, 2019
• Grant date: Aug 30, 2022
• Expiry date: Jun 4, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2710/20071
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a mutated HPV39 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV39 and HPV68, or HPV39, HPV68 and HPV70), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.